Reovirus enhances cytotoxicity of natural killer cells against colorectal cancer via TLR3 pathway

BACKGROUND: Cetuximab has been approved for use for first-line treatment of patients with wild-type KRAS metastatic colorectal cancer (CRC). However, treatment with cetuximab has shown limited efficacy as a CRC monotherapy. In addition, natural killer (NK) cell function is known to be severely atten...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Shiqi, Gu, Yangzhuo, An, Yuanyuan, Lin, Xiaojin, Chen, Xiaoqing, Wang, Xianyao, Liao, Chunxiang, Ouyang, Weiwei, Wang, Nianxue, He, Zhixu, Zhao, Xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088708/
https://www.ncbi.nlm.nih.gov/pubmed/33933132
http://dx.doi.org/10.1186/s12967-021-02853-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088708/
https://www.ncbi.nlm.nih.gov/pubmed/33933132
http://dx.doi.org/10.1186/s12967-021-02853-y

Ejemplares similares